NorthWest Biotherapeutics Inc (NWBO)

[hyperopia]

abeta, it means that about 23 out of every 100 patients treated with DCVax, would be expected to be alive at their 5-year milestone anniversary. For those patients that didn’t receive DCVax, and only received the standard of care, according to comparable historical trials, only about 7 out of 100 patients would be expected to reach their 5-year anniversary.

It does not mean that once a patient reaches their 5-year anniversary, that the chance of survival beyond that is 23%, if that is what you’re asking. The curve is nearly flat at that point, and there is anecdotal evidence with DCVax and other immunotherapies to suggest that once a patient lives beyond a certain point, usually around 3 or 4 years, the chance of continuing to survive is very high.